Biocon Biologics CEO Discusses Merger and IPO Plans

Biocon Biologics Managing Director and CEO Shreehas Tambe says the board has not recommended any action on a potential IPO or merger of the biosimilars unit. He shares his perspective...

By Bloomberg Markets · Bloomberg Markets

Biocon Biologics Managing Director and CEO Shreehas Tambe says the board has not recommended any action on a potential IPO or merger of the biosimilars unit. He shares his perspective on Bloomberg’s Insight with Haslinda Amin. (Source: Bloomberg)